Trial · NCT02117713
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) | Baseline to Week 48 | This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels. |
| Secondary | Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA) | Baseline to week 216 | The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels. |
| Secondary | Change From Baseline to Week 218 in Pruritus | Baseline to Week 218 | This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results. |
| Secondary | Change From Baseline to Week 216 in Alanine Aminotransferase | Baseline to week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels. |
| Secondary | Change From Baseline to End of Treatment in Alkaline Phosphatase | Baseline to Week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels. |
| Secondary | Change From MRX Baseline to Week 216 in Aspartate Aminotransferase | Baseline to week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels. |
| Secondary | Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score | Baseline to week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. |
| Secondary | Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score | Baseline to Week 216 | This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident. |
| Secondary | Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase | Baseline to Week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT. |
| Secondary | Mean Change From MRX Baseline to Week 216 in Total Bilirubin | Baseline to week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin. |
| Secondary | Mean Change From MRX Baseline to Week 216 in Direct Bilirubin | Baseline to week 216 | This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02117713/registered